The effect of tamoxifen on the pharmacokinetics of letrozole in female rats

Biopharmaceutics and Drug Disposition

Volumn 27, Issue 7, 2006, Pages 335-344

  Tao, X ^a   Brodie, A M H ^b   Nnane, I P ^a,c  

^a TEMPLE UNIVERSITY SCHOOL OF PHARMACY   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c CENTOCOR INC   (United States)

Author keywords

Drug drug interaction; Letrozole; Pharmacokinetics; Tamoxifen

Indexed keywords

CGP 44 645; CYTOCHROME P450; DRUG METABOLITE; LETROZOLE; TAMOXIFEN CITRATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENTIATION; DRUG STRUCTURE; ENZYME INDUCTION; FEMALE; NONHUMAN; RAT; RAT STRAIN; SINGLE DRUG DOSE;

ANIMALS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ESTROGEN ANTAGONISTS; FEMALE; HALF-LIFE; MOLECULAR STRUCTURE; NITRILES; RATS; RATS, SPRAGUE-DAWLEY; TAMOXIFEN; TRIAZOLES;

EID: 33750633029     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.514     Document Type: Article

References (21)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics 2005. CA Cancer J Clin 2005; 55: 10-30.
2. Kisanga ER, Gjerde J, Schjott J, Mellgren G, Lien EA. Tamoxifen administration and metabolism in nude mice and nude rats. J Steroid Biochem Mol Biol 2003; 84: 361-367.
3. Park WC, Jordan VV. Selective estrogen receptor modulators (SERMs) and their roles in breast cancer prevention. Trends Mol Med 2002; 8: 82-88.
4. Jordon VC. Tamoxifen: toxicities and drug resistance during the treatment and prevention of breast cancer. Ann Rev Pharmacol Toxicol 1995; 33: 195-211.
5. Burstein HJ. Aromatase inhibitors vs tamoxifen: a changing of the guard? MedscapeHematology-Oncology eJournal 2002; 5(1). Available at http://www.medscape.com/viewarticle/424077.
6. Brodie AMH, Njar VCO. Aromatase inhibitors and their application in breast cancer treatment. Steroids 2000; 65: 171-779.
7. Buzdar AU. Pharmacology and pharmacokinetics of the newer generation aromatase inhibitors. Clin Canc Res 2003; 9(Suppl.): 468-472.
8. Lu Q, Liu Y, Long BJ, Grigoryev D, Gimbel M, Brodie AMH. The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer. Breast Cancer Res Treat 1999; 57: 183-192.
9. Dowsett M, Pfister C, Johnston SRD, et al. Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer. Clin Cancer Res 1999; 5: 2338-2343.
10. Arora A, Potter JF. Aromatase inhibitors: current indications and future prospects for treatment of post-menopausal breast cancer. Drugs Pharmacol 2004; 52: 611-616.
11. Wirz B, Valles B, Parkinson A, Madan A, Probst A, Zimmerman A. CYP3A4 and CYP2A6 are involved in the biotransformation of letrozole (Femara). 7th North American ISSX Meeting. 1996; 10: 359.
12. Daniels L, Blankson EA, Henderson CJ, et al. Delineation of human cytochromes P450 involved in the metabolism of tamoxifen. Br J Clin Pharmacol 1992; 34: 153-154.
13. Jacolot F, Simon I, Dreano Y, Beaune P, Riche C, Berthou F. Identification of the cytochrome P450 IIIA family as the enzyme involved in the N-desmethylation of tamoxifen in human liver microsomes. Biochem Pharmacol 1991; 41: 1911-1919.
14. Zhao XJ, Jones DR, Wang YH, Grimm SW, Hall SD. Reversible and irreversible inhibition of CYP3A enzymes by tamoxifen and metabolites. Xenobiotica 2002; 32: 863-878.
15. White INH, Davies A, Smith LL, Dawson D, DeMatteis F. Induction of CYP2B1 and 3A1, and associated monooxygenase activities by tamoxifen and certain analogues in the livers of female rats and mice. Biochem Pharmacol 1993; 45: 21-30.
16. Pfister CU, Duval M, Godbillon J, et al. Development, application and comparison of an enzyme immunoassay and a high-performance liquid chromatography method for the determination of the aromatase inhibitor CGS 20,267 in biological fluids. J Pharm Sci 1994; 83: 520-524.
17. Colussi DM, Parisot CY, Lefevre GY. Plasma protein binding of letrozole, a new nonsteroidal aromatase enzyme inhibitor. J Clin Pharmacol 1998; 38: 727-735.
18. Tao X, Brodie AMH, Nnane I. The effect of tamoxifen on the pharmacokinetics-pharmacodynamics of letrozole in female rats. AAPS Annual Meeting Abstract, Salt Lake City, Utah, USA, 2004.
19. Schieweck K, Bhatnagar AS, Batzi C, Lang M. Anti-tumor and endocrine effects of non-steroidal aromatase inhibitors on estrogen-dependent rat mammary tumors. J Steroid Biochem Mol Biol 1993; 44: 633-636.
20. Hall SD, Thummel KE, Wathins PB, et al. Molecular and physical mechanisms of first-pass extraction. Drug Metab Dispos 1999; 27: 161-166.
21. Long BJ, Jelovac D, Handratta V, et al. Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in breast cancer model. J Natl Cancer Inst 2004; 96: 456-465.